Intellia Therapeutics’ CRISPR candidate NTLA-2002 shows promise in early clinical trial

Trending News ☀️

Intellia Therapeutics Intrinsic Value – Intellia Therapeutics($NASDAQ:NTLA), Inc announced interim data for its CRISPR therapeutic candidate NTLA-2002 from a Phase 1/2 trial in hereditary angioedema . NTLA-2002 is designed to lower the production of kallikrein protein which causes swelling attacks seen in patients with HAE. The results as of Jul. 27 data cut-off were generated from the initial six adult HAE patients who were part of the ongoing dose-escalation study. Notable findings include dose-dependent reductions in plasma kallikrein with mean reductions of 65% and 92% in the 25 and 75 mg dose cohorts, respectively. The declines were sustained for at least 16 weeks in the 25 mg cohort and eight weeks in the 75 mg cohort. In terms of HAE attack rates, with a single dose of NTLA-2002, the 25 mg cohort achieved a 91% mean reduction in HAE attacks over 16 weeks of observation. These results are promising for the use of NTLA-2002 as a treatment for HAE and suggest that it may be able to provide long-term relief from the condition.

Stock Price

Intellia Therapeutics is a biopharmaceutical company that uses CRISPR technology to develop therapies for genetic diseases. NTLA-2002 is Intellia’s lead CRISPR candidate and is currently being evaluated in an ongoing Phase 1/2 clinical trial for the treatment of transthyretin amyloidosis . Despite ATTR being a rare disease, there is significant unmet need for effective treatments. There are currently no approved therapies for ATTR, and existing treatments only address the symptoms of the disease. NTLA-2002 has the potential to be a disease-modifying therapy that targets the root cause of ATTR. In a Phase 1/2 clinical trial, NTLA-2002 has shown promise, with patients treated with the therapy demonstrating improvements in disease symptoms. The news of NTLA-2002’s promising clinical data caused Intellia’s stock to open at $66.0 on Friday. However, the stock price closed at $65.7, down 4.2% from the prior closing price of $68.6. Despite this slight dip, the overall outlook for Intellia remains positive, as the company continues to make progress with its clinical programs.

VI Analysis – Intellia Therapeutics Intrinsic Value

The company’s fundamentals are a reflection of its long term potential. The intrinsic value of the company’s shares is around $66.8, calculated by the VI Line. The stock is currently traded at $65.7, which is a fair price but is undervalued by 2%.

Summary

Intellia Therapeutics is a biotech company that uses CRISPR technology to develop treatments for genetic diseases. Despite promising early results, the stock price of Intellia Therapeutics dropped on the news of the clinical trial. This could be due to investor caution or concerns about the long-term viability of the company’s technology.